ArticleJournal of clinical medicine2026
Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab Plus Tremelimumab): A Single-Center Retrospective Study.
Keita Maki, Hiroaki Haga, Takashi Kaneko, Kyoko Hoshikawa, Tomohiro Katsumi, Fumiya Suzuki, Fumi Uchiyama, Takumi Hanatani, Yasuhito Hagiwara, Masashi Koto and 1 more
Abstract read
In one paragraphArticle in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Keita MakiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.ORCID 0009-0003-2035-1940 Hiroaki HagaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.ORCID 0000-0001-9355-1837 Takashi KanekoDepartment of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Kyoko HoshikawaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Tomohiro KatsumiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.ORCID 0000-0001-5670-7505 Fumiya SuzukiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Fumi UchiyamaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Takumi HanataniDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Yasuhito HagiwaraDepartment of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.ORCID 0000-0002-5612-5094 Masashi KotoDepartment of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan.ORCID 0000-0001-5623-4250 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
atezolizumab plus bevacizumabcarbon-ion radiotherapydurvalumab plus tremelimumabhepatocellular carcinomaimmune checkpoint inhibitorssystemic immunotherapy
Identifiers
PMID42513363
PMCPMC13411702
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390